{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:50:06Z","timestamp":1793677806599,"version":"4.5.1"},"reference-count":107,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.drudis.2023.103662","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T13:11:13Z","timestamp":1686402673000},"page":"103662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic"],"prefix":"10.1016","volume":"28","author":[{"given":"Bhanu","family":"Priya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srimadhavi","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivapriya","family":"Kirubakaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2023.103662_b0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1667\/RR13515.1","article-title":"DNA damage response genes and the development of cancer metastasis","volume":"181","author":"Broustas","year":"2014","journal-title":"Radiat Res"},{"key":"10.1016\/j.drudis.2023.103662_b0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/em.22087","article-title":"Mechanisms of DNA damage, repair, and mutagenesis","volume":"58","author":"Chatterjee","year":"2017","journal-title":"Environ Mol Mutagen"},{"key":"10.1016\/j.drudis.2023.103662_b0015","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrc3344","article-title":"Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer","volume":"12","author":"Sulli","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2023.103662_b0020","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1101\/gad.2021311","article-title":"Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications","volume":"25","author":"Polo","year":"2011","journal-title":"Genes Dev"},{"key":"10.1016\/j.drudis.2023.103662_b0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/09553009414551661","article-title":"DNA damages processed by base excision repair: biological consequences","volume":"66","author":"Wallace","year":"1994","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.drudis.2023.103662_b0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2203\/dose-response.05-037.Scott","article-title":"Low-dose radiation-induced protective process and implications for risk assessment, cancer prevention, and cancer therapy","volume":"5","author":"Scott","year":"2007","journal-title":"Dose Response"},{"key":"10.1016\/j.drudis.2023.103662_bib475","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/362709a0","article-title":"Instability and decay of the primary structure of DNA","volume":"362","author":"Lindahl","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2023.103662_bib476","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/mutage\/geh025","article-title":"Endogenous DNA damage in humans: a review of quantitative data","volume":"19","author":"Bont","year":"2004","journal-title":"Mutagenesis"},{"key":"10.1016\/j.drudis.2023.103662_bib471","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1140321","article-title":"ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage","volume":"316","author":"Shuhei","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.drudis.2023.103662_b0035","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMra0804615","article-title":"DNA damage, aging, and cancer","volume":"361","author":"Hoeijmakers","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2023.103662_b0040","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/jnci\/91.11.943","article-title":"Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer","volume":"91","author":"Peto","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.drudis.2023.103662_b0045","unstructured":"Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews\u00ae [Internet]. Seattle: University of Washington, Seattle; 1993\u20132023. [Published 4 September 1998. Updated 26 May 2022. Accessed 10 January 2023]."},{"key":"10.1016\/j.drudis.2023.103662_b0050","first-page":"6413","article-title":"Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein","volume":"89","author":"Frebourg","year":"1992","journal-title":"Genetics"},{"key":"10.1016\/j.drudis.2023.103662_b0055","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3390\/cancers3010994","article-title":"Role of p53 in cell death and human cancers","volume":"3","author":"Ozaki","year":"2011","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2023.103662_b0060","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2023.103662_bib472","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1126\/science.278.5340.1064","article-title":"Integrating genetic approaches into the discovery of anticancer drugs","volume":"278","author":"Hartwell","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.drudis.2023.103662_b0065","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/annonc\/mdt384","article-title":"PARP inhibitors for BRCA1\/2 mutation-associated and BRCA-like malignancies","volume":"25","author":"Lee","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2023.103662_b0070","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1016\/j.bmcl.2012.06.053","article-title":"Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family","volume":"22","author":"Finlay","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2023.103662_b0080","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.dnarep.2009.04.006","article-title":"Common mechanisms of PIKK regulation","volume":"8","author":"Lovejoy","year":"2009","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.drudis.2023.103662_b0075","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2023.103662_b0085","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3934\/biophy.2015.2.36","article-title":"Structure and assembly of the PI3K-like protein kinases (PIKKs) revealed by electron microscopy","volume":"2","author":"Rivera-Calzada","year":"2015","journal-title":"AIMS Biophys"},{"key":"10.1016\/j.drudis.2023.103662_b0090","doi-asserted-by":"crossref","first-page":"801c17","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2023.103662_b0095","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3390\/genes12081143","article-title":"DNA-dependent protein kinase catalytic subunit: the sensor for DNA double-strand breaks structurally and functionally related to ataxia telangiectasia mutated","volume":"12","author":"Matsumoto","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.drudis.2023.103662_b0100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0968-0004(00)01563-2","article-title":"FAT: a novel domain in PIK-related kinases","volume":"25","author":"Bosotti","year":"2000","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.drudis.2023.103662_b0105","doi-asserted-by":"crossref","first-page":"15741","DOI":"10.1074\/jbc.M513172200","article-title":"The FATC domains of PIKK proteins are functionally equivalent and participate in the Tip60-dependent activation of DNA-PKcs and ATM","volume":"281","author":"Jiang","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2023.103662_b0110","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.tibs.2017.09.001","article-title":"Sharing the SAGA","volume":"42","author":"Helmlinger","year":"2017","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.drudis.2023.103662_b0115","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1038\/sj.onc.1210605","article-title":"Orchestration of chromatin-based processes: mind the TRRAP","volume":"26","author":"Murr","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2023.103662_b0120","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1101\/gad.1666208","article-title":"TopBP1 activates ATR through ATRIP and a PIKK regulatory domain","volume":"22","author":"Mordes","year":"2008","journal-title":"Genes Dev"},{"key":"10.1016\/j.drudis.2023.103662_b0125","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ceb.2005.04.005","article-title":"Nonsense-mediated mRNA decay: molecular insights and mechanistic variations across species","volume":"17","author":"Conti","year":"2005","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.drudis.2023.103662_b0130","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2023.103662_bib473","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/cr.2007.111","article-title":"Regulation of DNA double-strand break repair pathway choice","volume":"18","author":"Shrivastav","year":"2008","journal-title":"Cell research"},{"key":"10.1016\/j.drudis.2023.103662_bib474","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1093\/emboj\/17.18.5497","article-title":"Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells","volume":"17","author":"Takata","year":"1998","journal-title":"The EMBO journal"},{"key":"10.1016\/j.drudis.2023.103662_b0135","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.dnarep.2004.03.021","article-title":"Role of DNA\u2013PK in the cellular response to DNA double-strand breaks","volume":"3","author":"Burma","year":"2004","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.drudis.2023.103662_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.07.002","article-title":"ATM in DNA repair in cancer","volume":"203","author":"Jin","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2023.103662_b0145","doi-asserted-by":"crossref","first-page":"8859","DOI":"10.1093\/nar\/gkx571","article-title":"A phosphorylation-and-ubiquitylation circuitry driving ATR activation and homologous recombination","volume":"45","author":"Dubois","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2023.103662_b0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00018-019-03365-1","article-title":"Structural basis of homologous recombination","volume":"77","author":"Sun","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.drudis.2023.103662_b0155","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.molcel.2016.12.007","article-title":"Coupling of homologous recombination and the checkpoint by ATR","volume":"65","author":"Buisson","year":"2017","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2023.103662_bib477","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nature01368","article-title":"DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation","volume":"421","author":"Bakkenist","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2023.103662_b0175","doi-asserted-by":"crossref","first-page":"13182","DOI":"10.1073\/pnas.0504211102","article-title":"A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM","volume":"102","author":"Sun","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103662_bib478","doi-asserted-by":"crossref","unstructured":"Y. Sun, et al., DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. Molecular and cellular biology, 2007;27:8502\u20138509.","DOI":"10.1128\/MCB.01382-07"},{"key":"10.1016\/j.drudis.2023.103662_bib479","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1126\/science.1108297","article-title":"ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex","volume":"308","author":"Lee","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.drudis.2023.103662_b0160","first-page":"5718968","article-title":"XRRA1 targets ATM\/CHK1\/2-mediated DNA repair in colorectal cancer","volume":"2017","author":"Wang","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.drudis.2023.103662_b0165","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/35071124","article-title":"The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis","volume":"410","author":"Falck","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2023.103662_b0170","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.3390\/biom5042877","article-title":"ATM-dependent phosphorylation of all three members of the MRN complex: from sensor to adaptor","volume":"5","author":"Lavin","year":"2015","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2023.103662_bib480","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/35018134","article-title":"Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response","volume":"406","author":"Shang","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2023.103662_bib481","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003277","article-title":"The interaction of CtIP and Nbs1 connects CDK and ATM to regulate HR\u2013mediated double-strand break repair","volume":"9","author":"Wang","year":"2013","journal-title":"PLoS genetics"},{"key":"10.1016\/j.drudis.2023.103662_bib482","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41467-018-07729-2","article-title":"ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks","volume":"10","author":"Balmus","year":"2019","journal-title":"Nature communications"},{"key":"10.1016\/j.drudis.2023.103662_b0180","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/s41467-019-09175-0","article-title":"UFL1 promotes histone H4 ufmylation and ATM activation","volume":"10","author":"Qin","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2023.103662_b0185","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1093\/nar\/gkz110","article-title":"MRE11 UFMylation promotes ATM activation","volume":"47","author":"Wang","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2023.103662_b0190","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1034\/j.1399-0004.1999.550501.x","article-title":"Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene","volume":"55","author":"Meyn","year":"1999","journal-title":"Clin Genet"},{"key":"10.1016\/j.drudis.2023.103662_b0195","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/(SICI)1098-1004(1997)10:2<100::AID-HUMU2>3.0.CO;2-O","article-title":"Diversity of ATM gene mutations detected in patients with ataxia-telangiectasia","volume":"10","author":"Concannon","year":"1997","journal-title":"Hum Mutat"},{"key":"10.1016\/j.drudis.2023.103662_bib483","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrc3007","article-title":"Strategies to improve radiotherapy with targeted drugs","volume":"11","author":"Begg","year":"2011","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.drudis.2023.103662_b0200","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1158\/0008-5472.CAN-12-1702","article-title":"Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR","volume":"73","author":"Liu","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2023.103662_b0205","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aat1719","article-title":"The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models","volume":"4","author":"Durant","year":"2018","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2023.103662_b0210","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jmedchem.6b00519","article-title":"Discovery of novel 3-quinoline carboxamides as potent, selective, and orally bioavailable inhibitors of Ataxia telangiectasia mutated (ATM) kinase","volume":"59","author":"Degorce","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103662_b0215","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.2174\/1568026620666200731174216","article-title":"Synthesis and characterization of quinoline-3-carboxamide derivatives as inhibitors of the ATM kinase","volume":"20","author":"Ravi","year":"2020","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.drudis.2023.103662_b0220","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1158\/1538-7445.AM2019-3500","article-title":"Abstract 3500: highly potent and selective ATM kinase inhibitor M4076: a clinical candidate drug with strong anti-tumor activity in combination therapies","volume":"79","author":"Fuchss","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2023.103662_b0225","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1535-7163.MCT-21-0934","article-title":"A new class of selective ATM inhibitors as combination partners of DNA double-strand break inducing cancer therapies","volume":"21","author":"Zimmermann","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2023.103662_b0230","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41594-021-00654-x","article-title":"Molecular basis of human ATM kinase inhibition","volume":"28","author":"Stakyte","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.drudis.2023.103662_b0235","doi-asserted-by":"crossref","first-page":"492","DOI":"10.18632\/aging.204487","article-title":"Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death","volume":"15","author":"Chiu","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.drudis.2023.103662_b0240","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/noaa238","article-title":"Brain exposure of the ATM inhibitor AZD1390 in humans\u2014a positron emission tomography study","volume":"23","author":"Jucaite","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.drudis.2023.103662_b0245","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1021\/acs.jmedchem.7b01896","volume":"61","author":"Pike","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2023.103662_b0250","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1186\/s12885-022-10084-7","article-title":"ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer","volume":"22","author":"Davis","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drudis.2023.103662_b0255","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1126\/science.1083430","article-title":"Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes","volume":"300","author":"Zou","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.drudis.2023.103662_b0260","doi-asserted-by":"crossref","first-page":"30357","DOI":"10.1074\/jbc.M705178200","article-title":"ATR pathway is the primary pathway for activating G2\/M checkpoint induction after re-replication*","volume":"282","author":"Lin","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2023.103662_b0265","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1126\/science.1065521","article-title":"ATR and ATRIP: partners in checkpoint signaling","volume":"294","author":"Cortez","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.drudis.2023.103662_b0270","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.dnarep.2004.03.032","article-title":"Dial 9\u20131\u20131 for DNA damage: the Rad9\u2013Hus1\u2013Rad1 (9\u20131\u20131) clamp complex","volume":"3","author":"Parrilla-Castellar","year":"2004","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.drudis.2023.103662_b0275","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.cub.2016.10.030","article-title":"RPA-binding protein ETAA1 is an ATR activator involved in DNA replication stress response article RPA-binding protein ETAA1 is an ATR activator involved in DNA replication stress response","volume":"26","author":"Lee","year":"2016","journal-title":"Curr Biol"},{"key":"10.1016\/j.drudis.2023.103662_b0280","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/ncb3422","article-title":"Activation of the ATR kinase by the RPA-binding protein ETAA1","volume":"18","author":"Haahr","year":"2016","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.drudis.2023.103662_b0285","doi-asserted-by":"crossref","first-page":"13660","DOI":"10.1073\/pnas.1007856107","article-title":"Reconstitution of RPA-covered single-stranded DNA-activated ATR-Chk1 signaling","volume":"107","author":"Choi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2023.103662_b0290","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-90-481-3471-7_7","article-title":"Function of TopBP1 in genome stability","volume":"50","author":"Sokka","year":"2010","journal-title":"Subcell Biochem"},{"key":"10.1016\/j.drudis.2023.103662_b0295","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1128\/MCB.21.13.4129-4139.2001","article-title":"ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1","volume":"21","author":"Zhao","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.drudis.2023.103662_b0300","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.embor.embor887","article-title":"Regulating mammalian checkpoints through Cdc25 inactivation","volume":"4","author":"Donzelli","year":"2003","journal-title":"EMBO Rep"},{"key":"10.1016\/j.drudis.2023.103662_b0305","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1038\/sj.emboj.7600328","article-title":"Chk1, but not Chk2, inhibits Cdc25 phosphatases by a novel common mechanism","volume":"23","author":"Uto","year":"2004","journal-title":"EMBO J"},{"key":"10.1016\/j.drudis.2023.103662_b0310","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2009.01.024","article-title":"Single-stranded DNA orchestrates an ATM-to-ATR switch at DNA breaks","volume":"33","author":"Shiotani","year":"2009","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2023.103662_b0315","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ng1129","article-title":"A splicing mutation affecting expression of ataxia\u2013telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome","volume":"33","author":"O\u2019Driscoll","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.drudis.2023.103662_b0320","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.dnarep.2004.03.025","article-title":"An overview of three new disorders associated with genetic instability: LIG4 syndrome, RS-SCID and ATR-Seckel syndrome","volume":"3","author":"O\u2019Driscoll","year":"2004","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.drudis.2023.103662_b0325","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4161\/cc.2.3.404","article-title":"Clinical impact of ATR checkpoint signalling failure in humans","volume":"2","author":"O\u2019Driscoll","year":"2003","journal-title":"Cell Cycle"},{"key":"10.1016\/j.drudis.2023.103662_b0330","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1101\/gad.14.4.397","article-title":"ATR disruption leads to chromosomal fragmentation and early embryonic lethality","volume":"14","author":"Brown","year":"2000","journal-title":"Genes Dev"},{"key":"10.1016\/j.drudis.2023.103662_b0335","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2023.103662_b0340","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ccr.2006.11.024","article-title":"p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK\/MK2 pathway for survival after DNA damage","volume":"11","author":"Reinhardt","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2023.103662_b0345","first-page":"4375","article-title":"Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, Caffeine1","volume":"59","author":"Sarkaria","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2023.103662_b0350","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fphar.2015.00147","article-title":"Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan","volume":"6","author":"Abu-Sanad","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2023.103662_b0355","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","article-title":"Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells","volume":"39","author":"Lloyd","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2023.103662_b0360","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours","volume":"125","author":"Middleton","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2023.103662_b0365","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2023.103662_b0370","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2018.36.15_suppl.2549","article-title":"Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors","volume":"36","author":"O\u2019Sullivan Coyne","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2023.103662_b0375","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1200\/JCO.2019.37.15_suppl.3067","article-title":"Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors","volume":"37","author":"Mittra","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2023.103662_b0380","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","article-title":"Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress","volume":"39","author":"Thomas","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2023.103662_b0385","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT271","article-title":"Abstract CT271: Translational analyses of ATR inhibitor M1774 in a Phase I study in patients with solid tumors (DDRiver Solid Tumors 301)","volume":"83","author":"Tolcher","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2023.103662_b0390","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT272","article-title":"Abstract CT272: Pharmacodynamic and immunophenotyping analyses of ATR inhibitor M1774 in a Phase I study in patients with solid tumors (DDRiver Solid Tumors 301)","volume":"83","author":"Plummer","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2023.103662_b0395","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1016\/j.annonc.2022.07.586","article-title":"457MO A phase I study of ATR inhibitor M1774 in patients with solid tumours (DDRiver Solid Tumours 301): Part A1 results","volume":"33","author":"Yap","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2023.103662_b0400","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0959-8049(22)01066-8","article-title":"Optimization of treatment schedule for the ATR inhibitor elimusertib (BAY 1895344) in preclinical tumor models","volume":"174","author":"Wengner","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.drudis.2023.103662_b0405","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2022.11.014","article-title":"Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma","volume":"168","author":"Harold","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.drudis.2023.103662_b0410","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR Inhibitor AZD6738 (Ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor Olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2023.103662_b0415","doi-asserted-by":"crossref","first-page":"e005041","DOI":"10.1136\/jitc-2022-005041","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer","volume":"10","author":"Kwon","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.drudis.2023.103662_b0420","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1200\/JCO.2021.39.15_suppl.8562","article-title":"The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer","volume":"39","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2023.103662_b0425","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy","volume":"33","author":"Kim","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2023.103662_b0430","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","article-title":"RP-3500: A novel, potent, and selective ATR inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors","volume":"21","author":"Roulston","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 1","key":"10.1016\/j.drudis.2023.103662_b0435","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.annonc.2022.01.068","article-title":"5MO comprehensive dose-finding strategy for single-agent RP-3500, a highly selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase","volume":"33","author":"Fontana","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2023.103662_b0440","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/1538-7445.AM2023-312","article-title":"Abstract 312: The ATR inhibitor ART0380 shows preclinical efficacy in monotherapy or in combination with gemcitabine, aPD1, PARP inhibitors and topoisomerase 1 poisons","volume":"83","author":"Majithiya","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2023.103662_b0445","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1538-7445.AM2019-369","article-title":"Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy","volume":"79","author":"Zenke","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2023.103662_b0450","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1158\/1538-7445.AM2023-6177","article-title":"Abstract 6177: ATRN-119 and ATRN-W1051: novel and potentially well tolerated ATR and WEE1 inhibitors for targeted cancer treatment","volume":"83","author":"Vacca","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2023.103662_b0455","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/cr.2017.158","article-title":"Cryo-EM structure of human ATR-ATRIP complex","volume":"28","author":"Rao","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.drudis.2023.103662_b0460","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.chembiol.2003.09.002","article-title":"The process of structure-based drug design","volume":"10","author":"Anderson","year":"2003","journal-title":"Chem Biol"},{"key":"10.1016\/j.drudis.2023.103662_b0465","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1021\/acs.jpcb.2c04344","article-title":"Evolving experimental techniques for structure-based drug design","volume":"126","author":"Aplin","year":"2022","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.drudis.2023.103662_b0470","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.74218","article-title":"Structure of the human ATM kinase and mechanism of Nbs1 binding","volume":"11","author":"Warren","year":"2022","journal-title":"Elife"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623001782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623001782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:05:19Z","timestamp":1761224719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644623001782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":107,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1359644623001782"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103662","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting ATM and ATR for cancer therapeutics: Inhibitors in clinic","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103662","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103662"}}